TEVA
Teva Pharmaceutical Industries Ltd
$31.46
▲ 1.5%Updated Today 3:42 PM ET
TEVA at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 33/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 106.5% over the last 12 months
Market Cap
$32.95B
P/E
25.77x
Forward P/E (est.)
—
ROE
20.7%
Revenue Growth
4.4%
EPS Growth
—
Profit Margin
9.0%
FCF Yield
-10.5%
Debt / Equity
2.12x
ROIC
5.0%
Interest Coverage
2.35x
Current Ratio
1.01x
Dividend Yield
—
Implied Growth (rev. DCF)
5.3%
Rating Score
33/100
Teva Pharmaceutical Industries Ltd (TEVA) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $32.95B.
In its latest reported year it generated about $17.26B in revenue and $1.41B in net profit.
Our model rates TEVA Weak (33/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
49.6% average over the last 3 years
±2.5 pts around 48.2% across 10 years
grew in 3 of the last 9 year-over-year periods
positive in 10 of 10 years
5.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what TEVA's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. TEVA trades near $31.46, around its 50-day average ($34.07) and 200-day average ($29.48). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 53 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. TEVA's is $1.16 (~3.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month TEVA found buyers near $30.80 (support) and sellers near $35.47 (resistance); its 52-week range is $14.99–$37.35. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.3× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
2.1%
Revenue moved from $21.90B in 2016 to $17.26B in 2025, a -2.6% compound annual growth rate. The most recent year was roughly flat (4.4%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
51.8%
Operating Margin
12.5%
Net Margin
8.2%
ROE
20.7%
Teva Pharmaceutical Industries Ltd keeps about 9.0% of each sales dollar as net profit, with a 51.8% gross margin and 12.5% operating margin. Return on equity is 20.7% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$28.83B
Net Debt
$25.09B
Net Debt / EBITDA
11.63x
Debt / Equity
2.12x
Leverage: debt-to-equity is 2.1x, and operating profit covers interest about 2.4x, with a current ratio of 1.0x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $28.83B of total debt against $3.74B of cash.
Operating CF
$1.65B
Free Cash Flow
$1.15B
FCF Margin
6.7%
In the latest year Teva Pharmaceutical Industries Ltd produced about $1.65B of operating cash flow and $1.15B of free cash flow after capital spending. That is a free-cash-flow yield of about -10.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Per share (latest FY)
$0.85
Total paid (latest FY)
$12.00M
History on record
3 years
dividend uses 1% of free cash flow
1% of net income paid out
no current raise streak
payout was cut at least once in the last 3 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
25.77x
P/S
2.34x
P/B
4.87x
EV / EBITDA
18.37x
TEVA trades at 25.8x trailing earnings, 2.3x sales, and 4.9x book value. Reverse-engineering today's price implies the market expects roughly 5.3% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$17.32
Current price
$31.46
Starting FCF (latest 10-K)
$1.15B
Growth, years 1–5
4.4%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where TEVA sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How TEVA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), TEVA ranks #73 of 324 by our overall rating. It trades at roughly in line versus the sector on earnings (25.8x P/E vs. 25.8x median) with a higher return on equity (20.7% vs. 14.1%) and slower revenue growth (4.4% vs. 7.6%).
P/E vs sector
25.8x
median 25.8x
ROE vs sector
20.7%
median 14.1%
Growth vs sector
4.4%
median 7.6%
Sector rank
#73
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $31.46 today · expected CAGR -4% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $17.95B | $18.67B | $19.41B | $20.19B | $21.00B |
| Net income | $1.44B | $1.49B | $1.55B | $1.62B | $1.68B |
| EPS | $1.37 | $1.43 | $1.48 | $1.54 | $1.60 |
| Share price (low) | $21.93 | $22.81 | $23.72 | $24.67 | $25.66 |
| Share price (high) | $35.64 | $37.06 | $38.55 | $40.09 | $41.69 |
| CAGR (low–high) | -30% / 13% | -15% / 9% | -9% / 7% | -6% / 6% | -4% / 6% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for TEVA:
- Strong return on equity (20.7%) shows capital is put to work well.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against TEVA:
- Elevated leverage (debt/equity 2.1x) adds financial risk.
- Interest coverage is thin (2.4x), so debt costs bite.
- Limited free cash flow at today's price.
- Our model's overall read is Weak (33/100).
Balance-sheet risk — debt/equity of 2.1x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Teva Pharmaceutical Industries Ltd is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 25.8x earnings, which our model scores Weak (33/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 7 Wall Street analysts covering TEVA recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
TEVA's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
TEVA — frequently asked questions
Is TEVA a good stock to buy?
We don't give buy or sell advice. Our model rates Teva Pharmaceutical Industries Ltd Weak (33/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is TEVA's rating on The Stocks School?
Teva Pharmaceutical Industries Ltd currently scores 33/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does TEVA's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Teva Pharmaceutical Industries Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for TEVA calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this TEVA analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell TEVA. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.